Adenosine News and Research

RSS

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ß-N9-glycosidic bond.

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

King Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection.

21 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Mention the words "bubble boy" and many will recall David Vetter, the kid with big eyes and a thick thatch of dark hair who died 25 years ago after spending almost the entire 12 years of his life in a germ-free, plastic bubble. David was born with severe combined immune deficiency, or SCID, a condition that robbed him of an immune system.

14 Oct 2009

ArQule completes patient enrollment in ARQ 197 Phase 2 trial for non-small cell lung cancer

ArQule, Inc. (Nasdaq: ARQL) today announced that patient enrollment in a Phase 2 trial with ARQ 197 in non-small cell lung cancer (NSCLC) has been completed.

5 Oct 2009

Breast milk should not be stored and fed later

The levels of the components in breast milk change every 24 hours in response to the needs of the baby. A new study published in the journal Nutritional Neuroscience shows, for example, how this milk could help newborn babies to sleep.

3 Oct 2009

Phase III PLATO study proves that ticagrelor is more effective than clopidogrel

New data from the phase III PLATO study showed that ticagrelor (BRILINTA((TM))) provided greater reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02% vs. 10.65%,>

25 Sep 2009

Genetically removing the osteopontin protein prevents lung diseases

In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).

16 Sep 2009

Comprehensive CT scan gives better indication of significant coronary artery disease

A team of researchers led by Massachusetts General Hospital (MGH) radiologists has developed a computed-tomography-based protocol that identifies both narrowing of coronary arteries and areas of myocardial ischemia - restricted blood flow to heart muscle tissue - giving a better indication of clinically significant coronary artery disease.

16 Sep 2009

HFSA's annual scientific meeting features four late breaking clinical trials

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured four late breaking clinical trials at the Hynes Convention Center in Boston.

15 Sep 2009

HFSA's 13th Annual Scientific Meeting focuses on causes and treatment of heart failure

The Heart Failure Society of America's (HFSA) 13th Annual Scientific Meeting convened Sunday, September 13, 2009 at the Hynes Convention Center in Boston. This three-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with this condition.

15 Sep 2009

Second-hand tobacco smoke exposure results in NAFLD

A team of scientists at the University of California, Riverside has found that even second-hand tobacco smoke exposure can result in nonalcoholic fatty liver disease (NAFLD), a common disease and rising cause of chronic liver injury in which fat accumulates in the liver of people who drink little or no alcohol.

11 Sep 2009

Aptamer nanoflares for molecular detection in living cells

By combining a gold nanoparticle with a unique family of nucleic acids, researchers at Northwestern University have created a new type of intracellular reporting system that with a flash of light reveals the presence and quantity of a wide variety of biologically important molecules. These so-called nanoflares could provide cancer biologists with a highly sensitive method of tracking complex biochemical processes in real time without interfering with those processes.

7 Sep 2009

PROTECT clinical study aimed at the assessment of rolofylline effects

Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.

2 Sep 2009

$201,339 grant offered to a professor for developing a database on enzyme functions

Since the advent of the Human Genome Project an explosion of data has sent the science world scrambling. There is a growing demand to fine-tune genomic codes, which list the "ingredients for life," but do not adequately explain how those ingredients function. A Rutgers University-Camden biochemist is addressing this knowledge gap through the creation of a database for quick "background checks" on all known enzyme functions. Thanks to a National Institute of Health grant, Peter Palenchar, an assistant professor of chemistry at Rutgers-Camden, will categorize decades-worth of scholarship on enzymes into a database, beginning with those that bind to molecules that contain adenosine.

27 Aug 2009

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.

25 Aug 2009

New research results reveal that two Parkinson genes can maintain the mitochondrial functions

Parkinson's disease is caused by the degeneration of neurons in the midbrain. The mechanisms leading to the loss of these neurons, however, are largely unknown. Recent research revealed that about ten per cent of cases are caused by defects in so-called Parkinson-associated genes. Furthermore, mitochondria, the cellular powerhouses, seem to play a major role. New results from researchers at the LMU Munich under the lead of associate professor Dr. Konstanze Winklhofer and Professor Christian Haass connect both phenomena, showing that two Parkinson genes maintain the function of mitochondria.

24 Aug 2009

Protein regulates movement of mitochondria in brain cells

Scientists have identified a protein in the brain that plays a key role in the function of mitochondria - the part of the cell that supplies energy, supports cellular activity, and potentially wards off threats from disease.The discovery, which was reported today in the Journal of Cell Biology, may shed new light on how the brain recovers from stroke.

15 Jun 2009

Better treatment selection and improved therapies hold the key to improving prognosis in acute heart failure

Today, acute heart failure represents the most common reason for hospitalisation in the over-65 population.

31 May 2009

Snoring and sleep apnoea damage the brain

Australian researchers have found that the effects of sleep apnoea on the brain of a sleeping patient are far worse than previously thought.

17 May 2009

Schering-Plough starts patient enrollment in phase 3 trial for Acadesine

Schering-Plough Corporation today announced the start of patient enrollment in RED-CABG, the Phase 3 Trial for acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA). Acadesine was licensed from PeriCor Therapeutics, Inc., a privately held specialty biopharmaceutical company.

12 May 2009